PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Geoffrey Bartholomeusz to Speak at Cell Based Assay Conference on November 6-8 in San Francisco, California - Geoffrey Bartholomeusz, Assistant Professor and Director of the siRNA Screening Service at the University of Texas MD Anderson Cancer Center, will speak about “The Third Dimension for High Throughput RNAi-Driven Target Identification” at the 8th Cell
Geoffrey Bartholomeusz to Speak at Cell Based Assay Conference on November 6-8 in San Francisco, California

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2013/09/09 - Geoffrey Bartholomeusz, Assistant Professor and Director of the siRNA Screening Service at the University of Texas MD Anderson Cancer Center, will speak about “The Third Dimension for High Throughput RNAi-Driven Target Identification” at the 8th Cell.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Geoffrey Bartholomeusz, Assistant Professor and Director of the siRNA Screening Service at the University of Texas MD Anderson Cancer Center, will speak about “The Third Dimension for High Throughput RNAi-Driven Target Identification” at the 8th Cell Based Assay & Screening Technologies Conference on November 6-8, 2013 in San Francisco, CA.

Although two-dimensional (2D) model systems have contributed to the understanding of tumor biology, these models fall short of reproducing the complex and dynamic environments of the tumor. This has led to the development of three-dimensional (3D) models, with the spheroid model being the most commonly used of these. Spheroid models take advantage of the cells’ natural tendency to aggregate and the cellular organization within the spheroids emulates the heterogeneity of solid tumors with necrosis and radiation-resistant hypoxic regions.

As the Director of the Screening Service at the MD Anderson Cancer Center, Dr. Bartholomeusz leads a team of highly trained individuals performing high throughput siRNA screens that utilize both 2D monolayer cell culture and 3D spheroid cell culture models. The team has developed a 3D spheroid cell culture model to address their hypothesis that silencing targets that regulate tumor architecture will alter the integrity of the tumor, reduce the hypoxic state and sensitize the tumor to radiation and/or chemotherapy. They used this model to perform a high throughput RNAi screen that used the activation of HIF-1 as the readout for selecting hits from the primary screen, and used alterations of hypoxic status of the inner core of the spheroid in the final validation and selection of the top ranked hits.

Dr. Bartholomeusz will share how he and his team identified and validated 5 unique targets whose silencing alters the integrity of the spheroid architecture. These results signify that the features of the third dimension, hypoxia, morphology and the heterogeneous growth characteristics of spheroids not present in 2D monolayer cell cultures makes their model necessary for studies in tumor biology.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Geoffrey Bartholomeusz to Speak at Cell Based Assay Conference on November 6-8 in San Francisco, California

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 infogtcbio[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow Ltd





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)